Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease

Abstract Background The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-direc...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Neil R. Parikh, Claudia Huiza, Jill S. Patel, Sonny Tsai, Nathisha Kalpage, May Thein, Sage Pitcher, Steve P. Lee, Warren S. Inouye, Mark L. Jordan, Homayoon Sanati, Lida Jafari, Carol J. Bennett, Greg E. Gin, Amar U. Kishan, Robert E. Reiter, Michael Lewis, Ahmad Sadeghi, William J. Aronson, Isla P. Garraway, Matthew B. Rettig, Nicholas G. Nickols
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2019-04-01
Цуврал:	BMC Cancer
Нөхцлүүд:	Oligometastases Prostate cancer Stereotactic body radiotherapy Abiraterone Apalutamide Leuprolide
Онлайн хандалт:	http://link.springer.com/article/10.1186/s12885-019-5496-5
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!